anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a medicine consisting of nitroglycerin pharmaceutical preparation having dermal administration form and capable of continuously improving portal hypertension without largely changing hepatic blood flow. CONSTITUTION:A dermal administration preparation of nitroglycerin used in remedy for cardiac infarction or angina pectoris is used as a long-term remedy for portal hypertension accompanied by cirrhosis of the lever. The preparation can be simply administered and exhibits prolonged portal hypertension improving action and used as ordinary use method. For example, in a commercial &#39;Millisrol(R)&#39; tape agent, the tape agent is applied to proper region (e.g. precordia) on skin surface of patient of portal hypertension. Though a well- known Vasopressin which is portal vein pressure depressing agent has strong side effects on circulatory organ, the aimed agent has no side effects.
A method and an apparatus for determining at least one smoothed data point (tk, sk) within a stream of data points {ti, si} with 1≤i≤z, k&lt;z is disclosed. Herein, the stream of data points {ti, si} is consecutively acquired in a manner that a data point (ti, si) is acquired after an acquisition of a preceding data point (ti-1, si−1), wherein each data point (ti, si) comprises a valid value or an invalid value or a missing value for the signal si at a time ti. Herein, the signal si at the time ti comprises physical, chemical, biological, environmental, and/or technical data acquired by means of a technical set-up. According to the method, a set of data points is provided, wherein for each smoothed data point (tk, sk) a smoothing set is created. For each smoothed data point (tk, sk), trailing data resulting from large gaps are removed until it is verified whether the smoothing set comprises a minimal number of data points. Thereafter, for each smoothed data point (tk, sk) an initial slope set is calculated, on which at least one exponential smoothing is applied, in which cause an at least once modified slope set is determined. By integrating the at least once modified slope set, a value for the smoothed data point (tk, sk) is determined and returned. The method provides a good degree of smoothing without introducing any lag time and with minimal distortions, and is capable of reporting derivatives for the set of smoothed data points at the same time. The method is particularly suited in real-time or nearly real-time measurements which may comprise large gaps within the stream of data points.
In one or more embodiments, a contract management system provides an alert sub-utility that includes web-based data mining tools to automatically detect changes to a carrier&#39;s website and a notification sub-utility for packaging and communicating these changes. These data mining tools parse through XML tags nested within a tree of the carrier&#39;s website and determine whether any changes have been made to the web document. These XML tags allow the data mining tool to focus its efforts in extracting particular data of interest. Once the changes of interest have been extracted, the notification sub-utility of one or more embodiments of the present invention creates and communicates an alert to the healthcare provider. The methods and systems of one or more preferred embodiments provide healthcare providers with a more focused and timely alert of changes to a carrier&#39;s policy. Further, they provide the health care provider with historical revenue data in combination with the policy change alerts.
A class of substituted azetidine, pyrrolidine and piperidine derivatives of formula (I) are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1D.alpha. receptor subtype relative to the 5-HT1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D  receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D  receptor agonists, wherein Z represents an optionally substituted six-membered heteroaromatic ring selected from pyridine, pyrazine, pyrimidine and pyridazine; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 4 carbon atoms, optionally substituted in any position by one or more substituents selected from fluoro and hydroxy; T  represents nitrogen or CH; U represents N or CR2. V = O, S or NR3. M &amp; R are as defined in the application.
Disclosed herein are compounds and methods to identify the direct RNA targets of small molecules in cells is described. The approach, dubbed   Chemical  Cross-Linking and Isolation by  P ull-down to  Map  Small Molecule-RNA Binding Sites (Chem-CLIP-Map-Seq), appends a cross-linker and a purification tag onto a small molecule. In cells, the compound binds to RNA and undergoes a proximity-based reaction. The cross-linked RNA is purified and then amplified using a universal reverse transcription (RT) primer and gene-specific PCR primers. At nucleotides proximal to the binding site, RT &#34;stops&#34; are observed. This approach has broad utility in identifying and validating the RNA targets  and  binding sites of small molecules in the context of a complex cellular system.
PROBLEM TO BE SOLVED: To provide a human neural stem cell stably suppliable without causing problems in compatibility during transplantation. SOLUTION: This cell is separated from a human amniotic mesenchymal cell layer and capable of expressing nestin and vimentin which are markers of the neural stem cell and incorporating 5-bromo-2&#39;-deoxy-uridine into the cell by culturing the cell in the presence of the 5-bromo-2&#39;-deoxy-uridine. Thereby, the cell can be collected in a large amount together with placenta and the collection of the cell is free from ethical problems. The cell can stably be supplied. Since the cell has immunological tolerance, there is no problem about the compatibility when the cell is transplanted to a patient. Therefore, the cell exhibits excellent effects as a drug delivery system, etc., for the substance produced with a neurocyte by transplanting the cell into the brain of the patient suffering from an intractable nervous disease such as Parkinson&#39;s disease and metabolic nervous disease.
Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient 5 clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-( 1-cyclohexyl-l I l-tetra/ole-5-yl)butoxy]3.4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in drainage a pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of 10 a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down&#39;s syndrome, or macular degeneration. 48
The invention concerns - the amyloid precursor protein --- binding protein and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases, e.g. Alzheimer&#39;s disease, malignant tumor, hemopathy, disorder of embryo development, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics therof. The invention also discloses the uses of the polynucleotide, which encodes the amyloid precursor protein---binding protein.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing an antibacterial deodorizer having antibacterial performance and high deodorizing performance.  &lt;P&gt;SOLUTION: This antibacterial deodorizer is made of inorganic oxide fine particles composed of a metal component and an inorganic oxide other than the metal component. The inorganic oxide comprises titanium oxide and silica and/or zirconia. The titanium oxide is crystalline titanium oxide. The metal component content in the inorganic oxide fine particles ranges between 0.1 and 30 wt.% expressed in terms of oxide, with the average particle size of the inorganic oxide fine particles ranging 2 to 500 nm in diameter.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Clostridium difficile  infection is the leading cause of hospital acquired antibiotic-associated diarrhea in the US (Bartlett, in 2006). The increased prevalence of circulating  C. difficile  strains poses a significant health threat to US health care facilities. Strains expressing the toxin  C. difficile  Transferase (CDT), in addition to Toxins A and B (TcdA and TcdB), are more virulent and are associated with higher mortality rates (Bacci et al., 2011). We recently identified a protective role for eosinophils against  C. difficile  pathogenesis (Buonomo et al., 2016). We have also defined CDT&#39;s ability to increase host inflammation and suppress protective eosinophils through a TLR2 dependent mechanism (Cowardin et al., 2016). How CDT promotes virulence and eosinophil suppression via TLR2 is still under investigation. We employed a genome-wide microarray approach to reveal divergent transcriptional profiles between protected (TLR2−/−) and unprotected (WT) mice infected with either CDT expressing or CDT mutant strains of  C. difficile.  This work revealed novel host mediated TLR2-dependent inflammatory pathways to CDT. We provide an unbiased framework for understanding the host immune response to the binary toxin CDT produced by  C. difficile  and how TLR2 signaling enhances virulence.
The present invention discloses an antitumor auxiliary medicament and a preparing method thereof. The auxiliary medicament comprises raw medicinal materials according to the proportioning by weight: 1 portion of liquorice root, 1 to 4 portions of ginseng, 1 to 3 portions of tangerine peel, 1 to 3 portions of fructus amomi, 3 to 5 portions of largehead atractylodesrhizome, 3 to 5 portions of glutinous rice root, 2 to 4.5 portions of pinellia tuber, 2 to 4.5 portions of cablin potchouli herb and 2.5 to 5 portions of malt. The medicinal preparation is a traditional Chinese medicine preparation for benefiting Qi, regulating the middle warmer, lowering the adverse flow of Qi , preventing vomit, promoting appetite and strengthening the spleen. The medicinal preparation can efficiently improve archenteric symptoms (nausea, vomit, poor appetite, oil aversion, abdominal distention, etc.) caused by the use of chemotherapeutic medicaments by tumor patients and can also relieve symptoms (weariness, etc.) generated during tumor patient&#39;s chemotherapy and after tumor patient&#39;s chemotherapy; the tumor patients&#39;life quality in various aspects is enhanced, and the medicinal preparation has the advantages of good therapeutic effect and little toxic or side effect.
To provide a biocompatible membrane composite that can provide an environment that is able to mitigate or tailor the foreign body response.SOLUTION: The membrane composite contains a mitigation layer and a vascularization layer. A reinforcing component may optionally be included to provide support to and prevent distortion of the biocompatible membrane composite in vivo. The mitigation layer may be bonded or adhered to an implantable device and/or cell system. The biocompatible membrane composite may be used as a surface layer for implantable devices or cell systems that require vascularization for function but need protection from the host&#39;s immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite may partially or fully cover the exterior of the implantable devices or the cell systems. The mitigation layer is positioned between the implantable device or a bioactive scaffold and the vascularization layer.SELECTED DRAWING: Figure 7
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair treatment composition facilitating the inhibition of the occurrence of unpleasant hardness in the hair when repairing a damaged hair protein with an ampholytic polymer compound, and to provide a method of hair treatment.  &lt;P&gt;SOLUTION: The hair treatment composition contains (A) the ampholytic polymer compound and (B) a diester. The hair treatment composition contains a polymer of monomers containing a cationic monomer, an anionic monomer and a nonionic monomer as the ampholytic polymer compound (A). The diester (B) is a diester of cyclohexane-1,4-dicarboxylic acid with polyoxyethylene alkyl ethers. The hair treatment composition preferably contains (C) amino acids besides them. The method of the hair treatment using the hair treatment composition includes subjecting the hair to hairdye treatment by coating a hairdye composition on the hair after applying the hair treatment composition to the hair.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present invention belongs to a medicinal formula and a preparation method thereof, particularly to a compound hairy holly injection which is proportionally prepared from various Chinese herbal medicines. A preparation method for the compound hairy holly injection comprises: the Chinese herbal medicines are processed by sieving, decocting, concentrating, ethanol precipitating, etc. The compound hairy holly injection is suitable for treating various kinds of virosis, and particularly has obvious curative effects on hepatitis B in initial stage, autumn diarrhea, upper respiratory tract infection and infant&#39;s capillary bronchitis. The total effective rate of the compound hairy holly injection reaches 96.7%. The compound hairy holly injection is an important medicine for paediatrics. The compound hairy holly injection has the advantages of stable effect and no toxic side effect, and has clinical practicality and pertinence. Thereby, the compound hairy holly injection is a good medicine with a special effect treating virosis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic preventing make up from coming off, and having a good make up maintenance.  &lt;P&gt;SOLUTION: The cosmetic is provided by incorporating with blending specific polyurethane particles in a cosmetic base agent. The specific polyurethane particles consist of polyurethane particle main bodies and a hydrophilic silica fine particles covering the surface of the particle main bodies. The polyurethane particle main bodies are obtained by three dimensionally polymerizing an isocyanate terminal urethane prepolymer obtained by the reaction of a polyisocyanate component with a polyol component containing a polytetramethylene glycol, by a polyfunctional amine having ≥3 functions. The polyurethane particles are obtained by the spray drying of mixed aqueous dispersion obtained by dispersing hydrophilic silica fine particles and the three-dimensionally polymerized polyurethane spherical materials in water, by using a spray-drying machine.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing tablets and device for the same, performing the discharge of the tablets by surely preventing the tablets from the attachment or peeling with a pushing-out pin and further producing the tablets in good accuracy and in a good efficiency by making its constitution as simple one.  &lt;P&gt;SOLUTION: This tablet X having a prescribed form is formed by filling a wet powdery material in a mold cavity 4 of a platy table 2 and compressing from upper and lower directions. A releasing agent layer Z is installed on the tablet X in the mold cavity 4 by feeding the releasing agent Y consisting of a dried powdery material on the tablet X in the mold cavity. By inserting a pushing-out pin 25 from an upper open end of the mold cavity 4, the tablet X in the mold cavity 4 is pushed out through the releasing agent layer Z toward the lower direction of the table 2 for discharging. The attachment of the tablet X with the pushing-out pin 25 is prevented by the releasing agent layer Z.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present disclosure describes a system for providing interactive, treatment-related promotions to, and receiving product orders form, a patient operating a medical measurement device, using the device to facilitate such promotion and product ordering. The system includes a medical measurement device that collects measurement data concerning the physiological condition of the patient. The device receives an invitation from a DME provider&#39;s server asking a user of the device if they would like to view a promotion. If the invitation is accepted, the promotion is presented on the device. The device user may be provided the option to purchase the promoted product using the device. A DME server selects the promotion sent to the device based at least in part on the treatment of the patient for which the medical measurement device is used.
A system 10 for supporting a user&#39;s life style such as their fitness or medical condition includes a plurality of users&#39; communications end stations 12, 18, 22 connected through at least two communications bearers such as wireless operators 14, telecom operators 20 or internet 24 to a proactive service server 28 by means of a communications bearers gateway 16, the server having a geographic location unit. A user profile, which is associated with a user upon registering to the service, is preferably periodically updated based on messages received from the user who wishes to be supported in following up an individual regimen tailored for him. Messages reporting the condition in which the user is being are received also from care service providers associated with the user. A set of supporting measures and a set of respective thresholds accommodated to the user are associated with a user according to his profile. The user profile is preferably periodically updated and analyzed, trends and deviations from the anticipated levels derived in accordance with the updated user profiles are automatically estimated. If deviations from the planned levels exceed respective thresholds the system preferably automatically activates respective supporting measures addressed to the respective user. The supporting measures provided could include notices, encouragements, winning a prize, warnings and alerts communicated to the user and/or to respective care service providers and are preferably tailored according to the location of the user.
&lt;P&gt;PROBLEM TO BE SOLVED: To reduce a burden of operation for registering medical data in a user medical facility into a regional medical cooperation server.  &lt;P&gt;SOLUTION: A registration terminal 10 installed in the medical facility 100 collects (obtains) various kinds of information relating to the examination (data relating to the examination) designated on a selection/registration screen, from an image server 20, a report management server 50, and an electronic medical chart server 80. Then, the registration terminal 10 generates link information on the basis of the various kinds of collected information (information accompanying medical image data, remark report data, and a user information record). Then, the registration terminal 10 transmits the generated link information to the regional medical cooperation server 90. Then, the regional medical cooperation server 90 registers the received link information to a registry.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention discloses dihydroartemisinin mPEG-PLGA nano particles and a preparation method thereof. The invention provides a preparation method of dihydroartemisinin mPEG-PLGA nano particles, which is simple and quick to operate, and overcomes the defects of poor water solubility and low bioavailability of dihydroartemisinin. The tannic acid-iron ion metal-polyphenol network structure has low cytotoxicity, can be degraded in an acidic tumor microenvironment, and can participate in the redox reaction of Fe &lt; 3+ &gt; and Fe &lt; 2+ &gt; due to the reducibility of tannic acid. Increases the ferrous ion concentration in tumor cells, triggers Fenton reaction, and improves the iron death induction effect of the dihydroartemisinin. Experimental results show that the dihydroartemisinin nano-particles can obviously inhibit proliferation and migration of 4T1 tumor cells, and the IC50 is greatly lower than that of free dihydroartemisinin. The dihydroartemisinin nanoparticle has good inhibition effect on tumor cells and has application prospect of being developed into a good anti-tumor drug.
PROBLEM TO BE SOLVED: To obtain a new compound having skin-beautifying and whitening effect, prevention of chapped skin and improving effect and excellent in safety. SOLUTION: This tranexamic acid derivative comprises an amide substance of a tranexamic acid derivative of the formula [(n) is 1-18] with a straight-chain amino alcohol and its salt, e.g. N-(3&#39;hydroxypropyl)-trans-4-aminomethyl-1 cyclohexanecarboxylic acid amide hydrochloride. The compound of the formula is obtained by reacting tranexamic acid or its reactive derivative with a straight-chain amino alcohol in a solvent (e.g. dichloroethane) at an ambient temperature to boiling point of the solvent for 1-8hr. When tranexamic acid is directly reacted, the reaction is preferably carried out in the presence of a condensing agent such as dicyclohexylcarbodiimide.  A skin preparation for external use of cosmetic, medicine, etc., is prepared by including at least one or more kinds of amide substance of the compound of the formula with a straight-chain aminoalchol and its salt in an amount of 0.001-20wt.% as an active ingredient.
PURPOSE:To obtain a new alkali metal salt of a zinc monoalkylphosphate consisting mainly of lamellar crystal grains, excellent in safety, smoothness, transparency feeling, etc., suitable as a cosmetic base, by a specific means using an alkali metal salt of a specific monoalkylphosphoric acid and a zinc salt as raw materials. CONSTITUTION:Firstly, a salt interchange reaction is carried out between an alkali metal salt of a monoalkylphosphoric acid of the formula [R is a 8-32C (un)saturated straight or branched chain hydrocarbon] with a neutralization degree of 0.8-1.2 (e.g. sodium monocetylphosphate) and a zinc salt of formula XmYn (X is Zn; Y is an inorganic or organic anion; m and n are integers corresponding to the valences of X and Y, respectively) (pref. water-soluble ZnSO4) pref. in a reaction solvent consisting of water or a mixed solvent composed of water and a water-soluble organic solvent such as acetone. Then, the pH level of the reaction mixture is adjusted to 2-6 with an alkali compound (pref. NaOH or KOH) to deposit the aimed compound in the form of crystal. The salt interchange reaction is pref. made at &gt;=70 deg.C.